Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

- After eight weeks of treatment, RAD001 halted tumor growth in 55% of advanced gastric cancer patients previously treated with chemotherapy

- Based on these promising data, Novartis will initiate a Phase III trial of RAD001 for advanced gastric cancer patients

- Gastric cancer is the second leading cause of cancer death worldwide with the majority of new cases occurring in East Asia

EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Data released today show RAD001 (also known as everolimus; proposed brand name Afinitor(R)) halted tumor growth in 55% of patients with advanced gastric cancer, a condition for which there are limited treatment options. In addition, 45% of patients in the study demonstrated some tumor shrinkage(1).

The data will be presented at the American Society of Clinical Oncology's 2009 Gastrointestinal Cancers Symposium on January 15.

The open label, single arm, multi-center Phase II study of 54 patients conducted in Japan, is designed to assess the efficacy and safety of RAD001 in patients with advanced gastric cancer whose disease progressed despite prior treatment. Patients enrolled in the trial were heavily pre-treated. All trial participants were from Japan and of Asian descent (1).

"There are very limited treatment options for patients who progressed despite the standard treatment for this aggressive cancer," said Atsushi Ohtsu, MD, PhD, Director, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan. "The results from this study demonstrate that RAD001 has the potential to provide an effective new option for these patients."

A global Phase III clinical trial program to evaluate the efficacy and safety of RAD001 monotherapy in approximately 500 advanced gastric cancer patients will begin enrollment this year.

"Most advanced gastric cancer patients eventually sto
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... SHANGHAI, Oct. 24, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation ... "Company"), a leading China-based pharmaceutical and biotechnology research ... has, through its main Chinese subsidiary, Shanghai ChemPartner ... River Laboratories International, Inc.,s ("Charles River") Shanghai research ...
... and HOPKINTON, Mass., Oct. 24, 2011 DxTerity ... (NASDAQ: CALP ) announced today that ... strategic collaboration that will allow researchers to perform DxTerity,s ... platform minimizing sample processing time without compromising data quality. ...
Cached Medicine Technology:ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform 2DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform 3DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Caliper's LabChip® Dx Platform 4
(Date:12/24/2014)... -- Researchers say they have used human embryonic stem ... sperm. While this had already been done using ... these types of cells -- called primordial germ cells ... according to the team at the University of Cambridge ... is one of the earliest events during early mammalian ...
(Date:12/24/2014)... Angeles, CA (PRWEB) December 24, 2014 ... wreak havoc on those who have an intolerance to ... to diarrhea, gas, bloating, migraine headaches, joint pain and ... gluten free diet plans that deliver safe and ... certain foods that trigger a gluten allergy reaction. These ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The ... is a professional and in-depth research report on ... introduces COC basic information, including its definition, classification, ... news analysis, etc. This report also presents product ... Production is separated by regions, technology and applications. ...
(Date:12/24/2014)... For nearly 20 years, June Cotner has ... and all of life's rites of passage. Here, she ... Ling, in Toasts: The Perfect Words to Celebrate ... Organized by category and containing many original toasts written ... this timely tome contains sayings famous and profound, suitable ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 As 2014 ... reminds homeowners that before investing time and money into ... a licensed professional that specializes in tankless and eco-friendly ... to replace their water heater in 2015 to research ... decision. , Greenstar Home Services specializes in ...
Breaking Medicine News(10 mins):Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2
... , EXTON, Pa., July 29 Kensey Nash Corporation (Nasdaq: ... results for its fourth quarter and fiscal year ended June 30, 2009 ... , , Joe Kaufmann, President and CEO, will be ... at 9:00 A.M. Eastern Time. , , ...
... American Association ... ... in Cancer Prevention Research , a journal of the American Association for Cancer Research, ... head and neck. Furthermore, African Americans had far less HPV infection than whites, which led ...
... , , , ARMONK, ... ) announced today that St. Elizabeth Healthcare is ... roll-out of electronic medical records to improve patient care and lower costs. ... ) , , Today, only 1.5 percent of U.S. hospital ...
... , COLUMBUS, Ohio, July 29 ... New Drug Application (ANDA) for Risperidone Oral Solution, 1mg/mL by ... in 30mL bottles for immediate shipment to wholesalers and pharmacies ... Solution, 1mg/mL are AA rated to RISPERDAL(R) (risperidone) oral solution. ...
... ... and share , ... Skokie, Ill. (Vocus) July 29, 2009 -- Tabyat Partners, LLC. ( www.tabyat.com ), a ... its Web-based communication portal iluvmydoc.com™ ( www.iluvmydoc.com ). The site offers interactive services to ...
... , BOSTON, July 29 Although acne ... extremely common in adult women. Studies show that acne affects more ... more than 25 percent of women between the ages of 40-49 ... to report having acne than men. While there is no cure ...
Cached Medicine News:Health News:Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference 2Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 2Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 3Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 4Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 2Health News:St. Elizabeth Healthcare Drives Kentucky's Largest Electronic Medical Records Initiative With IBM 3Health News:Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL 2Health News:Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 2Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 3Health News:Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: